- Home
- KOS vs MYGN Comparison
KOS vs MYGN Comparison
Compare KOS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- MYGN
- Stock Information
- Founded
- KOS 2003
- MYGN 1991
- Country
- KOS United States
- MYGN United States
- Employees
- KOS N/A
- MYGN N/A
- Industry
- KOS Oil & Gas Production
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KOS Energy
- MYGN Health Care
- Exchange
- KOS Nasdaq
- MYGN Nasdaq
- Market Cap
- KOS 870.4M
- MYGN 642.0M
- IPO Year
- KOS 2011
- MYGN 1995
- Fundamental
- Price
- KOS $1.75
- MYGN $7.68
- Analyst Decision
- KOS Buy
- MYGN Hold
- Analyst Count
- KOS 6
- MYGN 13
- Target Price
- KOS $4.32
- MYGN $13.50
- AVG Volume (30 Days)
- KOS 7.7M
- MYGN 1.4M
- Earning Date
- KOS 11-03-2025
- MYGN 11-06-2025
- Dividend Yield
- KOS N/A
- MYGN N/A
- EPS Growth
- KOS N/A
- MYGN N/A
- EPS
- KOS N/A
- MYGN N/A
- Revenue
- KOS $1,488,836,000.00
- MYGN $832,900,000.00
- Revenue This Year
- KOS N/A
- MYGN $0.17
- Revenue Next Year
- KOS $13.62
- MYGN $6.19
- P/E Ratio
- KOS N/A
- MYGN N/A
- Revenue Growth
- KOS N/A
- MYGN 3.83
- 52 Week Low
- KOS $1.39
- MYGN $3.76
- 52 Week High
- KOS $4.69
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- KOS 48.56
- MYGN 69.11
- Support Level
- KOS $1.65
- MYGN $7.13
- Resistance Level
- KOS $1.86
- MYGN $7.80
- Average True Range (ATR)
- KOS 0.10
- MYGN 0.44
- MACD
- KOS 0.02
- MYGN 0.05
- Stochastic Oscillator
- KOS 56.00
- MYGN 92.45
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.